Autologous Cultured Chondrocytes is under clinical development by Biosolution and currently in Phase II for Articular Cartilage Defect. According to GlobalData, Phase II drugs for Articular Cartilage Defect have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Autologous Cultured Chondrocytes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Autologous Cultured Chondrocytes overview
CartiLife belongs to cell therapy agent. It is formulated as solution for intraarticular route of administration. CartiLife is indicated for the treatment of knee cartilage defects.
CartiLife is under development for the treatment of articular cartilage defects. The drug candidate comprises of pellet-type extracellular matrix-associated autologous chondrocytes.
Biosolution overview
Biosolution is a developer, manufacturer and supplier of cell therapy products. The company’s product portfolio comprises skin target products, articular cartilage target products and anticancer drug products. It also offers epithelial models and organoid models of skin, cornea, oral mucosa and bronchial mucosa. The company also provides laboratory services such as medium-high throughput sequencing, analysis of DNA fragments for clinical research applications, gene expression application analysis, identification of genetic material and paternity testing, identification of bacteria, fungi and other microorganisms and absolute quantification of gene expression among others. Biosolution is headquartered in Seoul, South Korea
For a complete picture of Autologous Cultured Chondrocytes’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
